rethinkTHC Search
Menu
Study breakdown

Endocannabinoid Levels Are Elevated in Chronic Hepatitis C and May Worsen Liver Fibrosis

ObservationalPreliminary evidence
The takeaway

Patients with chronic hepatitis C had elevated endocannabinoid levels in their blood, and these endocannabinoids suppressed immune responses while potentially promoting liver scarring.

Read this if you have hepatitis C and use cannabis, or are interested in how the endocannabinoid system affects liver disease.

Endocannabinoids suppressed antiviral immunity and promoted liver scarring

What the researchers found

Researchers measured endocannabinoid levels in hepatitis C patients and found both anandamide and 2-AG were elevated in plasma compared to healthy controls. However, liver tissue levels and degrading enzyme activity were unchanged.

In immune cells, endocannabinoids suppressed the production of key antiviral and inflammatory cytokines (IFN-gamma, TNF-alpha, IL-2). The suppressive effect of anandamide on IL-2 was stronger in cells from hepatitis C patients than healthy controls.

In liver cells, 2-AG induced expression of inflammatory markers (IL-6, IL-17A, IL-32, COX-2) and enhanced activation of hepatic stellate cells (which produce scar tissue). This suggests endocannabinoids may simultaneously weaken the immune response to the virus while promoting liver fibrosis.

Why it matters

Cannabis use has been associated with faster fibrosis progression in hepatitis C patients. This study provides a mechanism: elevated endocannabinoids (which cannabis use would further increase) suppress antiviral immunity and promote liver scarring.

The numbers in context

AEA and 2-AG elevated in HCV patient plasma; hepatic FAAH and MAGL activity unchanged; endocannabinoids suppressed IFN-gamma, TNF-alpha, IL-2; 2-AG induced IL-6, IL-17A, IL-32, COX-2 in hepatocytes

How the study worked

Translational study measuring endocannabinoid levels by mass spectrometry in plasma and liver tissue of HCV patients. Enzyme activity assays, gene expression analysis, and co-culture experiments with immune and liver cells.

What this study cannot tell us

Observational study with in vitro functional experiments. Sample sizes not specified in the abstract. In vitro cell responses may not fully reflect in vivo liver biology. The hepatitis C treatment landscape has changed dramatically.

How to read the evidence

Translational study combining clinical measurements with mechanistic cell experiments. Provides biological plausibility but not clinical proof.

When this study was published

Published in 2015. Hepatitis C is now curable with direct-acting antivirals, but the endocannabinoid-liver fibrosis connection remains relevant for other liver conditions.

The bigger picture

This study connects cannabis-related liver disease progression to specific endocannabinoid mechanisms, providing biological support for clinical recommendations against cannabis use in chronic hepatitis C patients.

Questions still open

  • Does cannabis use directly worsen liver fibrosis in hepatitis C through these mechanisms? Would endocannabinoid system modulation improve hepatitis C treatment outcomes? Do these findings apply to other chronic liver diseases?

Common questions

Is cannabis bad for the liver?
This study found that elevated endocannabinoids in hepatitis C patients promoted liver scarring while suppressing antiviral immunity. Cannabis use would further increase endocannabinoid signaling, potentially worsening these effects.
Does this apply to people without hepatitis C?
The specific findings were in hepatitis C patients, but the endocannabinoid system plays roles in other liver conditions including fatty liver disease and alcoholic liver disease. Whether cannabis use worsens these conditions through similar mechanisms is an active research question.

Read the original research

Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation.

International journal of molecular sciences, 16(4), 7057-76

Citation

Patsenker, Eleonora; Sachse, Philip; Chicca, Andrea; Gachet, María Salomé; Schneider, Vreni; Mattsson, Johan; Lanz, Christian; Worni, Mathias; de Gottardi, Andrea; Semmo, Mariam; Hampe, Jochen; Schafmayer, Clemens; Brenneisen, Rudolf; Gertsch, Jürg; Stickel, Felix; Semmo, Nasser. (2015). Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation.. International journal of molecular sciences, 16(4), 7057-76. https://doi.org/10.3390/ijms16047057

Explore the wider topic